Please do not adjust margins
RSC Advances
Page 7 of 9
DOI: 10.1039/C5RA19617E
RSC Advances
COMMUNICATION
The work was supported by the National Natural Science
Foundation of China (No. 41276167, 41206066, 41506169 and
41306157), China Postdoctoral Science Foundation (No.
2015T80755 and 2014M551972), the National science and
technology support project (2013BAB01B02-2), Science and
Technology Development Program of Qingdao Shinan District
(NO. 2013-12-008-SW), Basic Research Projects of Qingdao
Science and Technology Plan (NO. 14-2-4-35-jch).
Author Contributions
Shuai-Yu Wang, Li-Jun Wang, and Da-Yong Shi contributed
to the study concept and design, and the manuscript
preparation. Li-Jun Wang and Shuai-Yu Wang performed the
experimental studies and analyzed the data. Bo Jiang, Ning Wu,
Xiang-Qian Li, Jiao Luo, Bao-Cheng Wang, Ren-Shuai Zhang and
6 for 24 h. Qi Xu contributed in critical reading and discussion on the
Fig. 9 HUVECs were incubated with 3–6µg/ml compound
Nitrite concentration was determined using the NO Kit. *p < 0.05 and **p < manuscript. All the authors approved the final version.
0.01 compared to the control.
Notes and references
Nitric oxide (NO) is a signalling molecule that plays
various roles pathologically and physiologically.22 In endothelial
cells, NO plays a key role in tumour angiogenesis. Finally, we
checked the NO production in HUVECs after treated with
1
J. S. I. Ferlay, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M.
Rebelo, D. M. Parkin, D. Forman and F. Bray, Cancer
Incidence and Mortality Worldwide: IARC Cance rBase No. 11
[Internet];GLOBOCAN 2012 v1.0 2013; International Agency
for Research on Cancer: Lyon, France, 2013. Available online:
S. K. Baloch, L. J. Ling, H .Y. Qiu, L. Ma, H. Y. Lin, S. C. Huang, J.
compound
reduced after treating HUVECs for 24 h (Fig.9). Above all,
compound was considered to have an antiangiogenic activity
6. The concentration of NO was significantly
6
2
L. Qi, X. M. Wang, G .H. Lu and Y. H. Yang, RSC Adv., 2014,
35588.
C. Huang, S. J. Yan, X. H. Zeng, B. Sun, M. B. Lan and J. Lin,
4,
in endothelial cells.
Conclusions
3
4
RSC Adv., 2015,
X. H. Wang, H. H. Su, C. S. Chen and X. F Cao. RSC Adv., 2015,
, 15597.
R. Goel, V. Luxami and K. Paul, RSC Adv., 2015,
5, 17444.
In summary, we synthesized a series of novel fluorinated
anticancer agents containing indolin-2-one moiety and
evaluated for their anticancer activities against A549, Bel7402,
HepG2, HeLa and HCT116 cancer cell lines by using MTT assay
5
5
6
5, 37887.
O. Afzal, S. Kumar, M. R. Haider, M. R. Ali, R. Kumar, M. Jaggi
and S. Bawa, Eur. J. Med. Chem., 2015, 96, 871.
in vitro. Among them, compounds
potent activity against the tested five human cancer cell lines.
Notably, compound showed significant activity against A549,
6, 7, 9, 12 and 13 showed
7
8
K. W. Wellington, RSC Adv., 2015,
Y. Q. Liu, J. Tian, K. Qian, X. B. Zhao, S. L. Morris-Natschke, L.
Yang, X. Nan, X. Tian and K. H. Lee, Med. Res. Rev., 2015, , 1.
5, 20309.
6
1
9
F. F. Li, J. G. Collins and F. R. Keene, Chem. Soc. Rev., 2015, 44,
2529.
Bel7402, HepG2, HCT116 and HeLa cancer cell lines with IC50
values of 5.10 ± 0.64, 4.40 ± 0.78, 3.30 ± 0.14, 4.40 ± 1.09 and
4.30 ± 0.77 μg/mL, which were comparable to those of
sunitinib. The further study on its mechanism demonstrated
10 M. Liu, P. E. Hansen and X. K. Lin, Mar. Drugs 2011, 9, 1273.
11 D. Y. Shi, J. Li, S. J. Guo, H. Su and X. Fan, Chin. J. Oceanol.
Limnol., 2009, 27, 277.
that compound
6 can be used as a potential anticancer agent
12 P. K. Li, Z. L. Xiao, Z. G. Hu, B. Pandit, Y. J. Sun, D. L. Sackett,
K. Werbovetz, A. Lewis and J. Johnsamuel, Bioorg. Med.
Chem. Lett., 2005, 15, 5382.
13 H. E. Dweedar, H. Mahrous, H. S. Ibrahim and H. A. Abdel-
Aziz, Eur. J. Med. Chem., 2014, 78, 275.
14 L. J. Wang, S. Y. Wang, B. Jiang, N. Wu, X. Q. Li, B. C. Wang, J.
for inhibiting proliferation and inducing apoptosis of cancer
cells, along with inhibiting angiogenesis of HUVECs. The further
studies on structural modifications and related mechanism of
action of these compounds are currently in progress, which
will be reported in future.
Luo, M. Yang, S. H. Jin and D. Y. Shi, Mar. Drugs, 2015, 13
806.
,
Acknowledgements
15 S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, Chem.
Soc. Rev., 2008, 37, 320.
16 W. K. Hagmann, J. Med. Chem., 2008, 51, 4359.
This journal is © The Royal Society of Chemistry 20xx
RSC. Adv., 2015, 00, 1-3 | 7
Please do not adjust margins